Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, are pivotal to its growth, generating $6.15 billion (48% of total revenue) in Q1 2025, driven by improved supply, international expansion, and U.S. pricing strategies. Analysts forecast continued strong performance for Q2, with Mounjaro estimated at $4.5 billion and Zepbound at $3.1 billion, as Lilly solidifies its position in the projected $100 billion U.S. obesity market alongside competitor Novo Nordisk. Despite a premium valuation (29.66x forward P/E), the company's robust pipeline and market leadership in this high-growth segment underpin its investment thesis.

Analysis

Eli Lilly's growth is predominantly fueled by its GLP-1 franchise, with Mounjaro and Zepbound generating a combined $6.15 billion in Q1 2025, constituting approximately 48% of the company's total revenue. This performance marks a significant rebound from a weaker second half of 2024, driven by tangible operational improvements including ramped-up production to ease supply constraints, successful international launches, and strategic U.S. pricing adjustments. Projections for the second quarter remain robust, with model estimates targeting $4.5 billion for Mounjaro and $3.1 billion for Zepbound, indicating sustained high demand. While the GLP-1 drugs are central, Lilly's broader portfolio, including oncology and immunology assets, continues to provide steady, albeit smaller, revenue contributions. The company operates as a duopoly with Novo Nordisk in a U.S. obesity market projected by Goldman Sachs to reach $100 billion by 2030, but faces emerging competition from firms like Viking Therapeutics. Despite its market leadership and strong stock performance, LLY carries a premium valuation with a forward P/E ratio of 29.66, nearly double its industry's average of 15.16, though this is below its own five-year mean. A recent minor downward revision in 2026 earnings estimates suggests a potential moderation in long-term growth expectations.

Key Decisions for Investors

• Investors should view the upcoming August 7 earnings report as a critical event, focusing on whether Mounjaro and Zepbound sales meet or exceed the high expectations set by Q2 forecasts.
• The premium valuation demands sustained, high-level execution; therefore, any signs of faltering demand, manufacturing delays, or pricing erosion present significant downside risk.
• While the stock's forward P/E is high, it may be justifiable for growth-focused portfolios given the company's dominant position in the expanding obesity market and its valuation remaining below its historical five-year average.
• Closely monitor the competitive landscape, particularly clinical trial data from emerging players like Viking Therapeutics and any strategic shifts by primary competitor Novo Nordisk, as these could impact Lilly's long-term market share.